On September 18, 2025, DBV Technologies, a clinical-stage biopharmaceutical company specializing in treatments for food allergies, announced the resignation of Daniel Soland from its Board of Directors, effective immediately. The announcement came from Michel de Rosen, Chairman of the Board, who expressed gratitude for Soland’s contributions since his appointment in 2015. His insights and expertise had been particularly valuable to the Board and its Compensation Committee. Soland noted his pleasure in serving on the Board and expressed optimism for the company's future, especially regarding the VIASKIN® Peanut patch, which aims to provide a much-needed treatment for peanut allergies in children.

Despite Soland’s departure, DBV Technologies will continue to function with its remaining nine board members. The Board plans to assess the timing and process for appointing a new member to fill the vacancy, with the appointment subject to shareholder approval at the next Annual General Meeting.

DBV Technologies is focused on developing non-invasive treatments for food allergies through its proprietary VIASKIN® patch technology, utilizing epicutaneous immunotherapy (EPIT) to help desensitize individuals to allergens via the skin. This innovative approach is particularly crucial, given the severity of food allergies, which affect millions, including young children. The company is currently engaged in clinical trials for its VIASKIN Peanut patch targeting both toddlers and children.

DBV Technologies is based in Châtillon, France, and operates in North America from Warren, New Jersey. Its shares are traded on Euronext Paris and the Nasdaq Capital Market. For further information, the company encourages engagement through its website and social media platforms.

The resignation of Daniel Soland from the Board of DBV Technologies is a noteworthy development that warrants careful consideration for investors. Having served on the Board since 2015, Soland provided invaluable experience and insight, particularly in relation to the company's flagship product, the VIASKIN® Peanut patch, aimed at treating peanut allergies in children. His departure prompts a necessary analysis of the potential implications for DBV Technologies' strategic direction and stability.

While the company asserts that its Board will continue functioning with its remaining members, a leadership change can often create uncertainty. Investors should closely monitor the composition of the Board in the coming weeks, especially regarding the appointment of Soland's replacement. The selection process and the skill set of the new member could influence the company's strategic initiatives, particularly as DBV ramps up efforts in clinical trials and seeks regulatory approval for its lead product.

DBV Technologies operates in a pivotal space within the biopharmaceutical sector, focusing on unmet medical needs in food allergies. As the company navigates the competitive landscape, the confidence of investors can be significantly impacted by advancements in clinical trials and regulatory milestones. Therefore, the ongoing clinical trials for the VIASKIN Peanut patch should be tracked closely. Successful results could have a strong positive impact on share prices, while any setbacks could lead to volatility.

For current and prospective investors, it is prudent to maintain a cautious optimism regarding DBV Technologies' potential. Monitoring upcoming communications from the company about the Board dynamics, clinical trial updates, and regulatory advancements will provide critical insights into the firm's trajectory and future performance in the market. Diversifying holdings could also mitigate risks associated with potential fluctuations in stock performance due to governance changes.